SCHEDULE: Squadron Entities Disclose Major Stake in Palisade Bio

Squadron Master Fund LP and affiliated entities have reported beneficial ownership of up to 8.5% of Palisade Bio, Inc.'s common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have filed a Schedule 13G disclosing their beneficial ownership in Palisade Bio, Inc.
• Squadron Master Fund LP beneficially owns 7,308,580 shares, representing 7.6% of the common stock.
• Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank each beneficially own 8,250,000 shares, representing 8.5% of the common stock.
• The ownership percentages are based on 96,645,431 shares of common stock outstanding as of October 1, 2025.
• The reporting persons disclaim beneficial ownership over the reported securities, stating the filing should not be construed as an admission of beneficial ownership.
• The securities were not acquired for the purpose of changing or influencing control of Palisade Bio, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by an institutional investor and its affiliates generally signals confidence in the company's prospects, which is a positive indicator for the market, even though the filing itself is purely factual.

Positives

• Significant institutional investment by Squadron Master Fund LP and its affiliates indicates a potential vote of confidence in Palisade Bio, Inc.
• The substantial stake (up to 8.5%) could provide a stable shareholder base for the company.

Risks

• The filing itself does not detail company-specific operational or financial risks. The primary risk related to this filing is the potential for future changes in ownership by these large holders, which could impact stock price volatility.
• The disclaimer of beneficial ownership by the investment advisor and individuals is a legal nuance, meaning they are not directly admitting to control, which could be interpreted in various ways regarding their long-term intentions, though it is standard for investment managers.

Industry Context

Significant institutional ownership disclosures like this are common in the biotechnology sector, where companies often rely on institutional capital for research and development. A substantial stake by an investment fund can signal market confidence, potentially attracting further investor interest, or it could be part of a broader investment strategy in the sector. This type of filing provides transparency regarding major shareholders.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor could be viewed positively, potentially increasing investor confidence and liquidity in Palisade Bio, Inc.'s stock.
• Management: A large institutional holder may exert influence on strategic decisions, although the filing explicitly states the acquisition was not for control purposes, suggesting a passive investment stance.

Key Dates

Recommendation

The filing is a factual disclosure of beneficial ownership by an institutional investor group. While a significant stake can be a positive signal, a Schedule 13G filing alone does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. It primarily indicates an existing position. Investors should 'hold' and await further operational or financial updates from Palisade Bio, Inc. to make a more informed decision, while acknowledging the presence of a notable institutional investor.

Keywords

Palisade Bio, Squadron Master Fund, Squadron Capital Management, Matthew Sesterhenn, William Blank, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology